Value Inflection Engineering
Explore a paper’s conversation or start a broader discussion below.
The cancer-vaccine option: finance the evidence before counting the payment
Merck–Moderna’s collaboration provides the timeline; a separate cash model tests option exercise, delay, settlement and the no-payment branch.
The Medicines We Never Get: Why Promising Science Fails to Reach Patients
Follow the decisions between a promising result and completed care—and distinguish scientific failure from avoidable execution gaps.
Clinical authorization and freedom to operate are separate milestones
The CRISPR patent appeal frames a hypothetical rights map, licensing sensitivity and IP diligence gate.
From Alpine to the next readout: define what the acquisition price did not resolve
A development-stage acquisition and a company-reported upcoming review date frame a fictional option-value model.
Buying an oncology platform does not buy a completed integration
Pfizer–Seagen provides transaction context for a fictional buyer’s integration reserve and portfolio gates.
The $22 billion headline is not the cash available to develop an ADC
A major ADC collaboration and a recent filing setback frame staged licensing, dilution and evidence-linked funding.
A royalty can finance the next mission—or be sold to fund it sooner
Cystic Fibrosis Foundation venture philanthropy frames a hypothetical royalty-retention and monetization decision.
The biotech value curve: define what changes at each evidence gate
A numerical framework for understanding why a milestone may change value—and why the calendar alone does not.
Biotech partnering: qualify the decision before building the contact list
Turn a leadership directory into a dated, evidence-based partnering process with measurable progression.
The founder translation gap: turn a scientific signal into a decision brief
A practical architecture for communicating clinical meaning, financing exposure and the work required for adoption.
AI value inflection: from technical promise to measurable enterprise value
A decision framework for separating clinical evidence, regulatory credibility and usable economic returns.
Read the deal structure: upfront value and contingent milestones are different
A large ADC collaboration illustrates why maximum announced consideration should be decomposed before it enters a value narrative.
Capital readiness: connect runway to the next credible evidence package
Recent industry financing data show why an aggregate recovery does not remove the need for company-level capital discipline.
Engineer the Phase II decision: milestones should retire a defined uncertainty
Historical transition rates help frame the challenge; the program’s evidence must determine the actual go, revise, or stop decision.
MiniMed 670G: a closed-loop claim needs one system evidence map
The 2016 hybrid system ties sensor, algorithm, pump, user tasks, and clinical evidence together.
CureVac’s CVnCoV: platform promise needs candidate-level stop rules
HERALD and the 2021 rolling-review withdrawal illustrate a portfolio decision after an incomplete success.
Cologuard: test sensitivity is the start of a screening pathway
The 2014 record connects a diagnostic metric to false positives, follow-up, and completed care.
Exubera: field scale cannot repair an unaccepted proposition
Pfizer’s 2007 exit makes adoption testing and reversible deployment financially concrete.
Aduhelm: an approval date was not an access-ready launch
The 2021–2024 sequence connects authorization, pricing, coverage, and the cost of stopping.
Ivacaftor: engineer a milestone around a defined mutation
The original G551D program shows how a focused evidence package can make a decision consequential.
Discussion
Share evidence, ask a question, or offer a professional perspective. Community guidelines
Loading discussion…